Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer.

Drug resistance is a major problem in patients with small cell lung cancer; in fact, most die of resistant disease, despite an initial response. Several markers of drug resistance have been described in preclinical models, but the mechanism of drug resistance in lung cancer patients remains unknown. The objective of this study was to evaluate the role of the expression of a number of markers of drug resistance, proliferation, and apoptosis in relation to response to chemotherapy and survival in patients with small cell lung cancer. Tumor samples were derived from 93 previously untreated patients who were randomized in a Phase III study to receive cyclophosphamide, epirubicine, and etoposide or cyclophosphamide, epirubicine and vincristine alternating with carboplatin and etoposide. Paraffin-embedded samples, derived from the primary tumor site prior to chemotherapy, were analyzed by immunohistochemistry for expression of markers implicated in drug resistance [topoisomerase (topo) IIalpha, topo IIbeta, and multidrug resistance-associated protein], apoptosis (p53, p21, and bcl-2), or proliferation (Ki67). Response prediction was analyzed by chi2 test and logistic regression analysis; overall and disease-free survival curves were compared by log-rank test and Cox regression analysis. Shorter survival was observed in patients with extensive disease (P = 0.037) and poorer performance status (P = 0.028) and in patients whose tumors expressed high topo IIalpha levels (P = 0.01) and high Ki67 (P = 0.024). By multivariate analysis, the following factors were found to be predictive for worse survival: high expression levels of topo IIalpha, Ki67, and bcl-2; male sex; and extensive disease. High topo IIbeta expression was found to be predictive for lower overall and complete response rate. No relationship between apoptotic pathway markers or MRP and response to chemotherapy was observed. In conclusion, high expression of topo IIalpha was predictive of worse survival, and high expression of topo IIbeta was predictive of lower response rates. Furthermore, lower survival probability was observed in patients with bcl-2-positive tumors. Immunohistochemical assessment of these markers in diagnostic biopsies may give important prognostic information and may help selecting patients in the worse prognostic categories for new therapeutic strategies.

[1]  J. Ben-Ezra,et al.  Small cell carcinomas of the lung express the Bcl-2 protein. , 1994, The American journal of pathology.

[2]  S. de Jong,et al.  Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. , 1990, Cancer research.

[3]  S. Hsu,et al.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  A. W. Boersma,et al.  Expression of the multidrug resistance-associated protein (MRP) gene in primary non-small-cell lung cancer. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Ueda,et al.  The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. , 1991, Oncogene.

[6]  H. Kreipe,et al.  Expression of bcl-2--protein in small cell lung cancer. , 1996, Lung cancer.

[7]  G. Giaccone,et al.  Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. , 1992, Cancer research.

[8]  I. Pastan,et al.  MDR1 gene expression in lung cancer. , 1989, Journal of the National Cancer Institute.

[9]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[10]  Costan,et al.  Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. , 1996, Cancer research.

[11]  Y. Jin,et al.  Immunohistochemical detection of Bcl-2 protein in small cell carcinomas. , 1996, Oncology.

[12]  G. Giaccone,et al.  Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[13]  C. Meijer,et al.  Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. , 1994, Cancer research.

[14]  N. Bleehen,et al.  Expression of apoptosis-regulatory genes in lung tumour cell lines: relationship to p53 expression and relevance to acquired drug resistance. , 1996, British Journal of Cancer.

[15]  G. Giaccone,et al.  Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. , 1995, Biochimica et biophysica acta.

[16]  J. Yokota,et al.  p53 mutations in human lung tumors. , 1992, Cancer research.

[17]  D. V. Von Hoff,et al.  Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. , 1992, Journal of the National Cancer Institute.

[18]  M. Sehested,et al.  Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization. , 1997, Cancer research.

[19]  G. Giaccone,et al.  Expression of drug resistance proteins in breast cancer, in relation to chemotherapy , 1997, International journal of cancer.

[20]  G. Capranico,et al.  DNA topoisomerase II poisons and inhibitors. , 1999, Cancer chemotherapy and biological response modifiers.

[21]  G. Zambetti,et al.  Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor , 1997, Molecular and cellular biology.

[22]  M. Tiemann,et al.  A new proliferation-associated nuclear antigen detectable in paraffin-embedded tissues by the monoclonal antibody Ki-S1. , 1993, The American journal of pathology.

[23]  G. Giaccone,et al.  Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  O. Dalesio,et al.  Small cell lung cancer. , 1988, Acta oncologica.

[25]  M. Fukuoka,et al.  p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  S. Bianchi,et al.  bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  M. Mattern,et al.  Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. , 1991, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  A. Duncan,et al.  Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. , 1992, Science.

[29]  John Calvin Reed,et al.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. , 1994, Oncogene.

[30]  M. Vlychou,et al.  Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas. , 1998, Anticancer research.

[31]  R. Parwaresch,et al.  Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-S1. , 1993, The American journal of pathology.

[32]  D. Mason,et al.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. , 1990, The American journal of pathology.

[33]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[34]  A. Harris,et al.  Differential expression of the topoisomerase II alpha and beta genes in human breast cancers. , 1996, British Journal of Cancer.

[35]  E. Podack,et al.  Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. , 1993, Biochemical and biophysical research communications.

[36]  R. Pieters,et al.  Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia. , 1995, Leukemia.

[37]  R. Ueda,et al.  Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[39]  D. Quinlan,et al.  Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.

[40]  W. Travis,et al.  Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response , 1996, Cancer.

[41]  A. Marchetti,et al.  p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. , 1996, Oncogene.

[42]  H. Kreipe,et al.  Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase II alpha. Delineation of a carboxy-terminal epitope with peptide antibodies. , 1995, The American journal of pathology.

[43]  Raouf Fetni,et al.  in UV-irradiated Human Skin Fibroblasts' , 1997 .

[44]  C. Harris,et al.  Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. , 1996, Journal of the National Cancer Institute.

[45]  亀崎 佐織.  bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair , 1996 .

[46]  W. Richards,et al.  Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  L. Zwelling,et al.  Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. , 1994, Blood.

[48]  J. Minna,et al.  Expression of bcl-2 in small cell lung carcinoma cells. , 1994, Cancer research.

[49]  S. Groshen,et al.  Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. , 1998, Journal of the National Cancer Institute.

[50]  K. Kimura,et al.  Analysis of M Phase-specific Phosphorylation of DNA Topoisomerase II* , 1996, The Journal of Biological Chemistry.

[51]  T. Lampidis,et al.  Multidrug-resistant gene expression in small-cell lung cancer. , 1997, American journal of clinical oncology.

[52]  A. Bernheim,et al.  Genistein resistance in human leukaemic CCRF-CEM cells: selection of a diploid cell line with reduced DNA topoisomerase II beta isoform. , 1995, Biochemical pharmacology.

[53]  L. Liu,et al.  Cellular resistance to topoisomerase poisons. , 1996, Cancer treatment and research.

[54]  S. Mirski,et al.  Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. , 1995, Cancer research.

[55]  S. Withoff,et al.  Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. , 1996, British Journal of Cancer.

[56]  A. Harris,et al.  p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. , 1996, Nucleic acids research.

[57]  D. Longo,et al.  Cancer chemotherapy and biological response modifiers annual , 1987 .

[58]  G. Giaccone,et al.  MRP is frequently expressed in human lung‐cancer cell lines, in non‐small‐cell lung cancer and in normal lung , 1996, International journal of cancer.

[59]  John Calvin Reed,et al.  Immunohistochemical analysis of the Bcl-2 oncoprotein in human neuroblastomas. Comparisons with tumor cell differentiation and N-Myc protein. , 1995, Laboratory investigation; a journal of technical methods and pathology.

[60]  Y. Nakanishi,et al.  Bcl-2 expression as a predictor of chemosensitivities and survival in small cell lung cancer. , 1996, The cancer journal from Scientific American.